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Cochrane reviewers are strongly encouraged to evaluate the quality of evidence for the
most important outcomes by using the GRADE approach and to report these results in a
Summary of Findings (SoF) table. We aimed to assess whether outcomes reported in the
SoF table of Cochrane reviews could be considered patient-important outcomes (PIOs) and
the quality of the available evidence for these outcomes.
Methods
We performed a methodological review of Cochrane reviews published between March
2011 and September 2014. For a random sample of Cochrane reviews reporting a SoF
table, we extracted all outcomes reported in this table and evaluated whether they could be
considered PIOs (i.e., mortality, other clinical events, adverse events, function, pain, quality
of life and therapeutic decisions). Then, we collected the quality of evidence for every out-
come in these SoF tables.
Results
We included 290 reviews issued by 47 of the 53 Cochrane Review Groups. Every SoF table
included a median of 5 outcomes, for a total of 1414 outcomes; 1089 (77%) could be consid-
ered PIOs. Almost all reviews (n = 278, 96%) included at least one PIO in their SoF table.
The quality of evidence for the outcomes was high for 12% (n = 168), moderate for 28%
(n = 402) and low or very low for 45% (n = 640). Less than one quarter of reviews (n = 63)
included at least one PIO with high-quality evidence that favoured a benefit of the experi-
mental intervention evaluated in half of them (n = 34 reviews).
Conclusions
Many outcomes reported in the SoF table of recent Cochrane reviews can be considered
PIOs. However, the quality of available evidence remains limited for these outcomes.
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Introduction
In the last decade, clinicians and researchers have been encouraged to recommend healthcare
interventions based on their effect on patient-important outcomes (PIOs) such as death, other
clinical events, quality of life or functional outcomes[1–6]. However, several methodological
reviews reported that the use of PIOs in randomized controlled trials (RCTs) of various medi-
cal specialities is still far from optimal [7–10]. In a recent report assessing trials of critically ill
patients, less than one quarter of primary outcomes (24%) were PIOs[9]. This proportion was
as low as 5% when exploring outcomes besides mortality after intensive care unit discharge,
such as functional disability or quality of life[9]. Similar results were previously found for dia-
betes[8] or cardiovascular [7] trials, with 18% and 23% of these trials assessing PIOs. In con-
trast, some recent studies suggested that systematic reviews are more likely to evaluate PIOs
than their individual trials[10, 11].
A key component of systematic reviews is the elaboration of a clear and focused clinical
question by specifying the types of participants, interventions, comparisons, and outcomes
that should be considered[12, 13]. When planning a Cochrane review, authors are strongly
encouraged to consider all outcomes that are meaningful to patients, physicians, policy makers
or any other health care stakeholders, regardless of their availability in individual trials [13,
14]. When reporting the review, they are asked to present a Summary of Findings (SoF) table
summarizing the quality of evidence and treatment effect magnitude for the most essential
outcomes for decision-making by using the Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) approach [13–18].
In this study, we aimed to evaluate: 1) whether outcomes reported in the SoF table could
be considered PIOs and 2) the quality of evidence for these outcomes in a sample of recent
Cochrane reviews.
Methods
This is a methodological review of recently published Cochrane reviews. For each Cochrane
review reporting an SoF table, we extracted all outcomes reported in this table and evaluated
whether they could be considered PIOs. Then, we evaluated the quality of evidence for these
outcomes.
Data sources
We previously obtained data from all systematic reviews published between March 2011 and
September 2014 from the Cochrane Collaboration [19]. Data were provided as XML files and
contained all information reported by the review authors using RevMan[20], the review soft-
ware developed by the Cochrane Collaboration to prepare and update systematic reviews.
Review selection
Using R 3.2.2 and the XML package, we identified all reviews of RCTs including at least one
SoF table. Reviews including observational studies were excluded. We also excluded reviews
including only trials published before 2007 to focus on recent topics. Then, we manually
examined all review titles and abstracts when necessary to select those evaluating a healthcare
intervention (pharmacological or non-pharmacological). Reviews evaluating diagnostic test
accuracy or economic evaluations were excluded. Among the set of eligible reviews, by using
a random number generator, we drew a random sample of 300 reviews for comprehensive
evaluation.
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Identification of the SoF for the main comparison
Most reviews have a single SoF table, but some have several, corresponding to different com-
parisons. In this case, we manually identified the main comparison as reported by the review
authors. If no main comparison was identified as such, we selected the one with the largest
number of available outcomes and included the largest number of trials. When the same SoF
table reported various comparisons, the review was excluded.
Data collection
For every included systematic review, we collected the following characteristics by using a
standardized data extraction sheet:
• Review general characteristics: title, digital object identifier (DOI), protocol publication
date, review first publication date, Cochrane Review Group (e.g., Gynaecological Cancer
Group), type of intervention (i.e., pharmacological or non-pharmacological), number of
excluded and included trials.
• Characteristics of the main comparison: Patient or population description, setting, interven-
tion and comparator
• Every outcome reported in the SoF table including outcome description and follow-up
period.
Classification of outcomes
We categorized each outcome as follows: mortality, other clinical events (e.g., myocardial
infarction or stroke), therapeutic decision (e.g., transfusion), function (e.g., anxiety, depres-
sion, disability and dyspnoea), pain, quality of life, adverse events or side effects (identified as
such by the review authors), physiological parameters (e.g., blood pressure, weight), biological
parameters (e.g., cholesterol levels), radiological parameters (e.g., measure of joint space),
compliance (e.g., discontinuation for any reason), process (e.g., duration of surgical proce-
dure), resource use (hospitalisations), cost-effectiveness and satisfaction with care. A single
reviewer classified all outcomes. As a quality measure, 10% of the outcomes were classified
independently in duplicate (YY and AD).
Definition of PIOs
We considered mortality, other clinical events, adverse events, function, pain, quality of life
and therapeutic decisions as PIOs consistent with previous studies [8, 11, 21, 22].
Quality of evidence
We evaluated the quality of evidence of each outcome reported in the SoF table based on the
review authors assessment. The evidence was classified as high quality if further research is
very unlikely to change the authors confidence in the estimate of effect; moderate quality if fur-
ther research is likely to have an important impact on the authors’ confidence in the estimate
of effect and may change the estimate; low quality if further research is very likely to have an
important impact on the confidence in the estimate of effect and likely to change the estimate;
and very low quality if the estimate of the effect is very uncertain[18]. We evaluated separately
the quality of evidence for outcomes that could be considered PIOs. For those considered
with high quality of evidence, we also evaluated whether this was evidence of benefit for the
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experimental intervention (results in favour of the experimental intervention: i.e., statistically
significant results).
Statistical analysis
The analysis was mostly descriptive. Continuous data are presented as median (Q1–Q3) and
qualitative data as frequency (percentage). All analyses involved use of R v3.1.1 (R Foundation
for Statistical Computing, Vienna, Austria. http://www.R-project.org/).
Results
Selection of relevant Cochrane systematic reviews
The selection process was previously described[19]. Briefly, between March 2011 and Septem-
ber 2014, 2796 Cochrane systematic reviews were published, 1670 did not include an SoF table
(60% of screened reviews) and 820 were eligible for inclusion. We identified a random sample
of 300 reviews, but 10 were additionally excluded because their SoF presented different inter-
ventions within the same table, which left 290 reviews for further evaluation.
Characteristics of included reviews
The reviews were issued by 47 of the 53 Cochrane Review Groups[23]. Every review included a
median of 11 trials overall (Q1-Q3: 5–21), with a median of 5 trials per main comparison
(Q1-Q3: 3–12)[19]. The experimental intervention was non-pharmacological in 40% of the
reviews (n = 115). Every SoF table included a median of 5 outcomes (Q1-Q3: 3–7), for a total
of 1414 outcomes. The corresponding meta-analyses included a median of 3 trials (Q1-Q3:
2–7).
Outcome classification
Among the 1414 outcomes reported in the SoFs, the most common were functional outcomes
(27%, n = 384), clinical events (14%, n = 198) and adverse events (12%, n = 174). Mortality rep-
resented 10% (n = 138) of the outcomes and quality of life 7% (n = 98). Among the outcomes,
biological parameters represented 6% (n = 89), process and resource use 5% (n = 74), and
physiological parameters and compliance 4% (n = 56) and 3% (n = 45). A total of 1089 out-
comes (77%, 95% CI: 75–79) could be considered PIOs (Table 1). Almost all reviews included
at least one PIO in the SoF table (n = 278, 96%; 95% CI: 93–98) (Fig 1). Per review, the median
proportion of PIOs among the outcomes reported in the SoF was 86% (Q1-Q3: 67–100).
Quality of available evidence
The quality of evidence provided by the outcomes in the SoF tables was high for 12% (n = 168,
95% CI: 10–14) and moderate for 28% (n = 402, 95% CI: 26–31) (Table 2). For 45% of the out-
comes (n = 640, 95% CI: 43–48), the quality of the evidence was low or very low. No GRADE
assessment was available for 12% of the outcomes (n = 164, 95% CI: 10–13) because according
to the review authors, these outcomes were not reported or measured in any individual trials.
The quality of the available evidence was very close when focusing on only PIOs, with 41%
(n = 449) having high and moderate evidence and 44% (n = 475) low to very low evidence.
Less than one-quarter of the reviews, 22% (n = 63; 95% CI: 17–27), included at least one
PIO with evidence considered of high quality by the review authors. In half (n = 34) of these
reviews, the results were in favour of the experimental intervention (i.e., statistically significant
results) (Fig 1).
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Discussion
In this study, we evaluated whether outcomes reported in the SoF table of recent Cochrane
reviews could be considered PIOs and the quality of evidence provided for these outcomes.
The large variety of review groups represented allowed us to explore very different medical
specialties. More than three-quarters of the outcomes reported in the SoF tables could be con-
sidered PIOs. However, for a large proportion of the available evidence (45%), the quality was
considered low or very low. About one quarter of the reviews included at least one PIO with
high-quality evidence and for half of them, this evidence showed a benefit of the experimental
intervention.
The Cochrane Collaboration strongly encourages review authors to include SoF tables to
present their main findings [13]. These tables, first introduced in Cochrane reviews in 2008,
aim to synthesize in a simple, transparent and accessible format, key information on the
assessed interventions’ magnitude of effect, sum of available data for the main outcomes and
quality of evidence [13]. Therefore, SoF tables should include the most important outcomes
whether they were measured in individual trials or not[13]. Previous studies reported that as
compared with reviews without SoF tables, the inclusion of SoF tables seemed to improve
readers’ general understanding of the reviews and allowed them to better identify the critical
information and find results for important outcomes (93% vs 44%)[24]. However, not all
Cochrane reviews present a SoF table. In our study, we excluded 60% of Cochrane reviews
because they had no SoF table, which is consistent with a previous study showing a proportion
of inclusion of SoF tables evolving from 31% in 2008 to 57% in 2013 [25]. An alternative ver-
sion of the SoF table called the interactive SoF (iSoF) allowing review authors to choose
Table 1. Classification of outcomes reported in the Summary of Findings (SoF) table in 290 recent Cochrane
reviews.
No. (%)
N = 1414 
Patient-important outcomes (PIOs)
Function 384 (27%)
Other clinical events 198 (14%)
Adverse events—side effects 174 (12%)
Mortality 138 (10%)
Quality of life 98 (7%)
Pain 71 (5%)
Therapeutic decision 33 (2%)
PIOs among the SoF table outcomes 1089 (77%; 95% CI 75–79)
Other outcomes
Biological parameter 89 (6%)
Process, resource use 74 (5%)
Physiological parameters 56 (4%)
Compliance 45 (3%)
Satisfaction with care 24 (2%)
Radiological parameters 23 (2%)
Cost-effectiveness 16 (1%)
The total is higher than N = 1414 because some outcomes were included in more than one category 95% CI, 95%
confidence interval
https://doi.org/10.1371/journal.pone.0195460.t001
Quality of evidence for patient-important outcomes in Cochrane reviews
PLOS ONE | https://doi.org/10.1371/journal.pone.0195460 April 5, 2018 5 / 9
alternative displays (absolute effects rather than relative effects) is being tested[26], which may
help generalise their use.
We found that most of the outcomes reported in the SoF tables could be considered PIOs,
with a median proportion of PIOs in the SoF tables of 86%. In a study that focused on recently
published Cochrane and non-Cochrane reviews but also on registered systematic reviews pro-
tocols (PROSPERO), Ameur et al described that 95% of Cochrane reviews included at least
one PIO among their primary outcomes. This proportion was higher than for non-Cochrane
reviews[11]. Two previous studies also found consistent results, with 68% to 71% of the
reviews considering PIOs as primary outcomes[21, 22]. A large survey of the completeness of
Fig 1. Patient-important outcomes in a random sample of Cochrane reviews.
https://doi.org/10.1371/journal.pone.0195460.g001
Table 2. Quality of available evidence for outcomes reported in the SoF tables for the main comparison in 290 recent Cochrane reviews.
All outcomes PIOs
N = 1414 N = 1089
Quality of
evidence




High quality Further research is very unlikely to change our confidence in the estimate of effect. 12 12
Moderate quality Further research is likely to have an important impact on our confidence in the estimate of effect and may
change the estimate.
28 29
Low quality Further research is very likely to have an important impact on our confidence in the estimate of effect and
likely to change the estimate.
28 27
Very low quality We are very uncertain about the estimate. 17 16
No GRADE No individual trial reported or measured the desired outcome 12 12
No GRADE Other reasons 3 3
https://doi.org/10.1371/journal.pone.0195460.t002
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main outcomes mapped the availability of information for a major clinical outcome across
randomized trials and systematic reviews in an entire discipline: 75% of reviews reported the
major clinical outcome as compared with only 20% of primary trial reports [27]. All these
results highlight the gap in outcomes between systematic reviews and their individual trials,
which may explain why the quality of evidence was frequently limited for the outcomes
reported in the SoF table, as shown by our results. In our study, only 22% of the reviews had at
least one PIO with a high level of evidence, with half showing a benefit of the experimental
intervention. The failure to consider PIOs in clinical trials may lead to erroneous evaluation of
benefits, with possible serious consequences for patients, and represents waste[28–31]. To
improve this situation, core outcome sets (COSs) should be developed (ie, standardized sets of
outcomes, that have been agreed upon, and that should be measured and reported in every
trial for a specific healthcare condition) and their use promoted [32–34]. The number of COSs
developed is still limited but is progressively increasing, such as their use in systematic reviews
[11, 25, 33, 35–37].
Our study has limitations. Although we relied on detailed and previously published defini-
tions for PIOs, considerable judgment remains when assessing the importance of the out-
comes, and patients or experts in the assessed medical field were not involved in this
evaluation. Our results cannot be generalized to all systematic reviews because Cochrane
reviews have precise conduct and reporting guidelines[13–15] and were described as more
transparently reported than all other types of systematic reviews[38]. Our study confirms that
many outcomes reported in the SoF tables of recent Cochrane reviews can be considered
PIOs. However, the quality of evidence for these outcomes remains limited.
Conclusions
Our study confirms that many outcomes reported in the SoF tables of recent Cochrane reviews
can be considered PIOs. However, the quality of evidence for these outcomes remains limited.
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